Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 4/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperidine SCHEMBL11775250 | 0.88 | ALDH1A1 (0.60) | ALDH1A1CXCR4SMN1; SMN2 | |
| Piperidine SCHEMBL9800122 | 0.88 | ALDH1A1 (0.60) | ALDH1A1CXCR4SMN1; SMN2 | |
| Piperidine SCHEMBL3005686 | 0.88 | — | — | |
| Piperidine SCHEMBL27896621 | 0.88 | ALDH1A1 (0.60) | ALDH1A1CXCR4SMN1; SMN2 | |
| Piperidine SCHEMBL6188975 | 0.87 | ALDH1A1 (0.45) | ALDH1A1CXCR4SMN1; SMN2DNM1MEN1 | |
| Piperidine SCHEMBL8175441 | 0.85 | DNM1 (0.55) | ALDH1A1DNM1MEN1KMT2ATSHR | |
| Piperidine SCHEMBL4128881 | 0.84 | ALDH1A1 (0.64) | ALDH1A1CXCR4SMN1; SMN2 | |
| Piperazine SCHEMBL6685072 | 0.84 | HIF1A (0.43) | ALDH1A1CXCR4SMN1; SMN2DNM1MEN1 | |
| Piperidine SCHEMBL8740912 | 0.84 | ALDH1A1 (0.64) | ALDH1A1CXCR4SMN1; SMN2 | |
| Piperazine SCHEMBL4260232 | 0.84 | HIF1A (0.43) | ALDH1A1CXCR4SMN1; SMN2DNM1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807382-B1 | CARBOXY ALKYL-ESTER ANTI-AGGLOMERANTS FOR THE CONTROL OF NATURAL GAS HYDRATES | CHAMPIONX USA INC (US) | 2025-06-18 | — | — | EP | disclosed |
| US-11174235-B2 | Carboxy alkyl-ester anti-agglomerants for the control of natural gas hydrates | CHAMPIONX USA INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3807382-A1 | CARBOXY ALKYL-ESTER ANTI-AGGLOMERANTS FOR THE CONTROL OF NATURAL GAS HYDRATES | ChampionX USA Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| US-6479482-B2 | 4-(3-((((3-(4-((3-METHYLBUTYL)AMINO)-1-PIPERIDINYL)PROPYL) -AMINO)-CARBONYL)AMINO)PHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-3,5 -PYRIDINEDICARBOXYLIC ACID, DIMETHYL ESTER DIHYDROCHLORIDE, FOR EXAMPLE; ANOREXIANT; NEUROPEPTIDE Y (NPY) | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-12 | — | — | US | disclosed |
| US-20020019384-A1 | Alkylamine derivatives of dihydropyridine NPY antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-14 | — | — | US | disclosed |
| WO-2001085173-A1 | ALKYLAMINE DERIVATIVES OF DIHYDROPYRIDINE NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019384-A1 | Alkylamine derivatives of dihydropyridine NPY antagonists | NPY1R, NPY2R, NPY4R | ALDH1A1 4112/4885CXCR4 1528/4885SMN1; SMN2 2849/4885 |
| US-11174235-B2 | Carboxy alkyl-ester anti-agglomerants for the control of natural gas hydrates | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AQP1, AQP3 | ALDH1A1 3057/4885CXCR4 1652/4885SMN1; SMN2 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.